CD34 Antibody ICO-115 | V2065 NSJ Bioreagents

	Catalog No	Formulation	Size	Price (USD)
	V2065-100UG	0.2 mg/ml in 1X PBS with 0.1 mg/ml BSA (US sourced) and 0.05% sodium azide	100 ug	519
Formulation
	V2065-20UG	0.2 mg/ml in 1X PBS with 0.1 mg/ml BSA (US sourced) and 0.05% sodium azide	20 ug	229
Formulation
	V2065SAF-100UG	1 mg/ml in 1X PBS; BSA free, sodium azide free	100 ug	519
Formulation

›

Surface flow cytometric analysis of CD34 on KG-1 cells using CD34 antibody (ICO-115, red) and isotype control antibody (green). The PPI-negative cell population was gated for analysis.

SDS-PAGE Analysis of Purified, BSA-Free CD34 Antibody (clone ICO-115). Confirmation of Integrity and Purity of the Antibody.

Species Reactivity	Human, Rat
Format	Purified
Clonality	Monoclonal (mouse origin)
Isotype	Mouse IgG1, kappa
Clone Name	ICO-115
Purity	Protein G affinity chromatography
Buffer	1X PBS, pH 7.4
Gene ID	947
Localization	Cell surface
Applications	ELISA (order BSA/sodium azide-free format for coating) : Flow cytometry : 1-2ug/10^6 cells Immunofluorescence : 0.5-1ug/ml
Limitations	This CD34 antibody is available for research use only.
	Review this product on BioCompare and get a $20 Amazon gift card

Description

This antibody recognizes a single chain, transmembrane, heavily glycosylated protein of 90-120kDa, which is identified as CD34. Its expression is a hallmark for identifying pluripotent hematopoietic stem or progenitor cells. Its expression is gradually lost as lineage committed progenitors differentiate. CD34 is a marker of choice for staining blasts in acute myeloid leukemia. In addition, it is expressed by soft tissue tumors, such as solitary fibrous tumor and gastrointestinal stromal tumor. CD34 expression is also found in vascular endothelium. Additionally, it appears that proliferating endothelial cells overexpress this molecule than the non-proliferating endothelial cells. Anti-CD34 labels > 85% of angiosarcoma and Kaposis sarcoma, but shows low specificity.

Application Notes

The concentration stated for each application is a general starting point. Variations in protocols, secondaries and substrates may require the antibody to be titered up or down for optimal performance.